Skip to content
Agree.net – Lifestyle
Author:
Spyre Therapeutics, Inc.
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
April 13, 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
April 13, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
April 3, 2026
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
March 16, 2026
RideNow Group, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
March 10, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
March 6, 2026
←
Previous Page
1
2